Phase 2 study
- United States
LG Chem Announces Topline Results of LC350189 From the Phase 2 Study (CLUE Study) Promising to Be a New Treatment Alternative With Improved Efficacy and Safety Profiles for Chronic Gout Patients
Seoul, South Korea & Cambridge, Mass., United States: LC350189 showed significant serum uric acid (sUA)-lowering effects across all dose levels.…
Read More » - Health
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure®/ Dysport® (abobotulinumtoxinA)
Lausanne, Switzerland: Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the…
Read More »